Neuropeptide Y Suppression After Heart Ablation May Contribute to Atrial Fibrillation Recurrence

Multi-omics profiling identified NPY as significantly downregulated after pulmonary vein ablation. NPY suppression promoted cardiomyocyte apoptosis and activated the Akt pathway in cardiac fibroblasts, increasing fibrosis. NPY intervention alleviated atrial myocyte apoptosis and inhibited Akt activation in fibroblasts. The atrial effective refractory period was shortened after ablation.

Animal study using a long-term beagle dog model after circumferential pulmonary vein ablation (CPVA). Transcriptome profiling via high-throughput sequencing and proteome analysis via TMT-tagged LC-MS. Differentially expressed genes and proteins were identified, with NPY selected for functional validation in cell experiments and tissue analysis.

Atrial fibrillation affects millions worldwide and catheter ablation is a primary treatment, yet recurrence rates remain frustratingly high. Understanding that NPY suppression after ablation actively promotes the conditions for recurrence opens a potential therapeutic avenue — supplementing NPY could help prevent AF from coming back.

This study connects neuropeptide signaling to cardiac arrhythmia in a new way. While NPY is best known for its roles in appetite and stress, its cardiac protective effects could represent a new therapeutic target for preventing AF recurrence — a major unmet need in cardiology.

Canine model may not fully replicate human cardiac physiology after ablation. The number of dogs used was not specified. The molecular pathway (NPY → apoptosis/fibrosis → AF reinduction) is proposed but the causal chain needs further validation. Translating NPY supplementation to human therapy faces significant pharmacological challenges.